Distinct impact of letermovir discontinuation on tacrolimus pharmacokinetics based on concomitant azole antifungal agent. (PubMed, Int J Hematol) - Jun 16, 2025 - "Although some antifungal agents influence the pharmacokinetics of tacrolimus after the discontinuation of letermovir, the effect of posaconazole (PSCZ) has not been previously described...The fold-change in the C/D ratio (post-/pre-discontinuation) was significantly higher in the PSCZ group compared with the fluconazole group (median 1.23 vs 0.83, P = 0.003)...Furthermore, the tacrolimus C/D ratio could increase following letermovir discontinuation in patients receiving PSCZ. Careful monitoring of tacrolimus concentrations at letermovir discontinuation is crucial to avoid an unexpected reversal of tacrolimus concentrations and prevent adverse events."
Journal • PK/PD data • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease • Transplantation
|
|
Akihiro Shimizu; Daichi Sadato; Hiroaki Shimizu; Koki Narita; Noriko Doki; Sotaro Goto; Takashi Toya; Yasuhiko Yamamura; Yuho Najima
|